Elective Endoscopic Gallbladder Treatment: Pilot Study

Cholecystolithiasis Clinical Trial

— SLATAN  

Official title:

Elective Endoscopic Gallbladder Treatment in Elderly Patients With Benign Gallbladder Diseases at High Surgical Risk: a Prospective Pilot Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05723224
• Other study ID #: 4569
• Status: Recruiting
• Phase: N/A
• Start date: June 14, 2022
• Est. completion date: December 24, 2023

Study information

• Verified date: January 2023
• Source: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
• Contact: Alberto Larghi
• Phone: +390630156580
• Email: alberto.larghi[@]yahoo.it
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Laparoscopic cholecystectomy (LC) represents the gold standard for treatment of elective and acute of gallbladder diseases, such as acute cholecystitis (AC). However, in elderly patients or in those with severe comorbidities, urgent LC can be associated with increase morbidity (up to 41%) and mortality (up to 19%). In these patients, placement of a percutaneous gallbladder drainage catheter (PT-GBD) or colecistostomy can be utilized to drain the gallbladder until infection is resolved, as a bridge to subsequent surgery or as definitive treatment. PT-GBD, however, is associated with major adverse events (AEs): intra-hepatic hemorrhage, pneumothorax, biliary peritonitis, bile leak from the site of drainage, AC recurrency, self-removal of the drainage by the patient e/o for spontaneous migration. Recently, to overcome PT-GBD limitations, EUS-guided gallbladder drainage (EUS-GBD) has been introduced as an alternative minimally invasive therapeutic intervention for treatment of patients with high surgical risk who present with AC. The procedure has high technical and clinical success rates and favorable safety profile, with low risk of recurrent AC. EUS-GBD, followed, when needed, by intra-cholecystic endoscopic interventions has been utilized even in relatively young patients as recently reported with successful intra-cholecystic giant stones clearance through the LAMS using previously described endoscopic lithotripsy in patients who rejected surgery and desired gallbladder preservation. A second category of patients who might benefit from EEGBT are elderly individuals with major comorbidities posing them at high surgical risk, who suffer from previous episodes of cholecystitis, recurrent colic episodes due to gallbladder stones, or with biliary acute pancreatitis due to stones migration. Based on all the above considerations, we have designed a prospective, pilot study to evaluate the safety and efficacy of elective EEGBT performed using LAMS stent with electrocautery-enhanced delivery system, followed by intra-cholecystic endoscopic interventions when needed in elderly patients with benign gallbladder diseases at high surgical risk, in whom an indication to perform cholecystectomy was indicated.

Description:

Laparoscopic cholecystectomy (LC) represents the gold standard for treatment of elective and acute of gallbladder diseases, such as acute cholecystitis (AC). However, in elderly patients or in those with severe comorbidities, urgent LC can be associated with increase morbidity (up to 41%) and mortality (up to 19%). In these patients, placement of a percutaneous gallbladder drainage catheter (PT-GBD) or colecistostomy can be utilized to drain the gallbladder until infection is resolved, as a bridge to subsequent surgery or as definitive treatment.4 PT-GBD, however, is associated with major adverse events (AEs), such as intra-hepatic hemorrhage, pneumothorax, biliary peritonitis and pneumonia that occur in about 6.2% of patients. Moreover, PT-GBD has several disadvantages including risk of bile leak from the site of drainage, AC recurrency, self-removal of the drainage by the patient e/o for spontaneous migration (0-25%), with the need for a repeat procedure to reposition the drainage catheter. Finally, percutaneous drainage causes discomfort for the patient, it is often associated with localized pain at the placement site, and can be felt as a cosmetic disfigurement. Recently, to overcome PT-GBD limitations, EUS-guided gallbladder drainage (EUS-GBD) has been introduced as an alternative minimally invasive therapeutic intervention for treatment of patients with high surgical risk who present with AC. This procedure has been strongly facilitated by the introduction of lumen-apposing metal stents (LAMSs), allowing adherence of the mobile gallbladder with the gastric/duodenal lumen and formation of a permanent fistulous tract through which therapeutic maneuvers are feasible, rendered EUS-GBD highly safe. The procedure has high technical and clinical success rates and favorable safety profile, with low risk of recurrent AC. Several retrospective studies and meta-analyses favored EUS-GBD over PTGBD. However, recently updated Tokyo guidelines still prefer PT-GBD as a primary treatment for high surgical risk AC patients, leaving EUS-GBD as a valid option only for experienced endosonographers working in high volume centers. approach has been utilized even in relatively EUS-GBD, followed, when needed, by intra-cholecystic endoscopic interventions has been utilized even in young patients as recently reported in a very provocative case series,that demonstrated successful intra-cholecystic giant stones clearance through the LAMS using previously described endoscopic laser lithotripsy in five patients with a mean age of 50 years, who rejected surgery and desired gallbladder preservation. After removal of LAMS, the fistula was closed with clips or spontaneously, with no gallstone recurrence in any patient after a mean 8-month follow-up. A second category of patients who might benefit from EEGBT are elderly individuals with cardiac, respiratory and other major comorbidities posing them at high surgical risk, who suffer from previous episodes of cholecystitis, recurrent colic episodes due to gallbladder stones, or with biliary acute pancreatitis due to stones migration. Based on all the above considerations, we have designed a prospective, pilot study to evaluate the safety (i.e., adverse events rate) and efficacy (i.e., clinical success rate) of elective EEGBT performed using LAMS stent with electrocautery-enhanced delivery system, followed by intra-cholecystic endoscopic interventions when needed in elderly patients with benign gallbladder diseases at high surgical risk, in whom an indication to perform cholecystectomy was indicated.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: December 24, 2023
• Est. primary completion date: June 14, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 75 Years and older

Eligibility

Inclusion criteria

• Age =75 years
• Benign gallbladder diseases with an indication to perform cholecystectomy
• high surgical risk (ASA score =3)
• Signed written informed consent Exclusion criteria
• Patients unwilling to undergo follow-up assessments
• Age <75 years
• Low surgical risk (ASA score <3)
• Patients with suspected gangrene or perforation of the gallbladder
• Ongoing acute cholecystitis
• Altered anatomy of the upper gastrointestinal tract due to surgery of the esophagus, stomach and/or duodenum
• Abnormal coagulation (INR > 1.5 and/or platelets < 50.000/mm3)
• Contraindication to perform endoscopy
• Inability to give informed consent

Related Conditions & MeSH terms

• Cholecystitis
• Cholecystitis, Chronic
• Cholecystolithiasis
• Cholelithiasis
• Gallstones

Intervention

Procedure:
• elective endoscopic gallbladder treatment
Access to the gallbladder will be performed from the stomach or duodenum using LAMS with electrocautery-enhanced delivery system such as Hot Axios, Boston Scientifics device or Hot Spaxus, Taewoong at the discretion of the endoscopist. A stent of 10 mm in diameter will be used if the largest gallstone will be smaller than 10 mm in size while greater diameter (=15 mm stent) will be used if the largest gallstone will be larger than 10mm. Colecystoscopy lithotripsy will be performed, when needed, using mechanical lithotripsy and/or laser lithotripsy at the discretion of the endoscopist. First cholecystoscopy will be done 2 weeks after the index procedure

Locations

Country	Name	City	State
Italy	Fondazione Policlinico Universitario Agostino Gemelli	Rome

Sponsors (1)

Lead Sponsor	Collaborator
Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of adverse events (AEs) after EUS-guided gallbladder treatment	AEs will be classified as procedural when they occur during the procedure; post-procedural when they will occur up to 14 days after the procedure; late when they will occur more than 14 days after the procedure. Minor AEs will be those that need no therapy and have no sequelae (A) or have minor therapy or consequence, including overnight admission (B). Major events include those that require major therapy or hospitalization (24- 48 hours) (C); major therapy, need unplanned increase in level of care, or hospitalization >48 hours (D); or result in permanent adverse sequelae (E) and death (F).	1 year
Secondary	Rate of Technical success	Number of patients achieving successful placement of the LAMS stent between the gastric/duodenal cavity and the gallbladder	1 year